ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING. Central Valley Public Health: Women's Way

Similar documents
BCCCP Approved ICD-9 Code List Fiscal Year 2010

Schedule of Fees for Covered Services

CMS Limitations Guide Mammography & Bone Mass Measurement

Women s Imaging ICD-10-CM

Understanding Your Pap Test Results

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two

Sponsored by: INOVA August 19, Presented by: Teri Romano, RN, MBA, CPC, CMDP CONNECT WITH US AT

ICD-10-CM Practical Guidance for Pathologists and Labs

DATA REQUEST RESPONSE- XRT AND BRACHYTHERAPY

Clinical Practice Guidelines June 2013

Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013

MALIGNANT NEOPLASMS OF THE BREAST MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS

What is a Pap smear?

NON-RECOMMENDED CERVICAL CANCER SCREENING IN ADOLESCENT FEMALES. HEDIS (Administrative)

CEA (CARCINOEMBRYONIC ANTIGEN)

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Breast Carcinoma The Hard Way

Department of Health Standard for the Cervical Cancer Screening Program. Approval Date: 08 May 2018 Effective Date: 13 May 2018

Case Study 1. Cervical Cancer Screening and Sexually Transmitted Infections Case Studies

What is cervical cancer?

BC Cancer Cervix Screening 2015 Program Results. February 2018

Becoming a colposcopist: Colposcope case studies

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Methods of Obstetrics & Gynecology treatment

HPV and Cervical Cancer, Screening and Prevention. John Ragsdale, MD July 12, 2018 CME Lecture Series

Chapter 10: Pap Test Results

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

Chapter 28. Breasts and Mammary Glands

1.Acute and Chronic Cervicitis - At the onset of menarche, the production of estrogens by the ovary stimulates maturation of the cervical and vaginal

January 15, 2009 (202) PROPOSALS TO IMPROVE CYTOLOGY PROFICIENCY TESTING REQUIRED BY THE CLINICAL LABORATORY IMPROVEMENT AMENDMENTS OF 1988

Workshop for O& G trainees and paramedics 17 Dec 2011 Cytological Interpretation

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

Introduction to Colposcopy

Understanding My Pap Test Results

PRE TEST CERVICAL SCREENING MANAGEMENT COLPOSCOPY PATHOLOGIC DIAGNOSIS AND TREATMENT

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Cytology and Surgical Pathology of Gynecologic Neoplasms

BREAST PATHOLOGY MCQS

The Gynecological Exam. Pelvic Exams and Cervical Cancer Screening. Learning Objectives. Focused History

ICD-10 Common Codes. ICD-10 Code. ICD-10 Code. Diagnoses. Diagnoses

2015 Gastroenterology Survival Guide

The society for lower genital tract disorders since 1964.

REPORTABLE CASES MISSISSIPPI For cases diagnosed 10/1/2015 and after

Carcinoembryonic Antigen

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

Department of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal

Twenty-first refresher course. Chan Kit Sheung

uterine cancer endometrial cancer

Female Reproduc.ve System. Kris.ne Kra7s, M.D.

14. Cancer of the Cervix Uteri

Cervical Precancer: Evaluation and Management

Effect of human papillomavirus vaccination on cervical cancer screening in Alberta

Making Sense of Cervical Cancer Screening

Eradicating Mortality from Cervical Cancer

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Int. J. Life. Sci. Scienti. Res., 2(3): (ISSN: ) Impact Factor 2.4 MAY Research Article (Open access)

LOUISIANA MEDICAID PROGRAM ISSUED: 11/25/14 REPLACED: 10/16/14 CHAPTER 48: FAMILY PLANNING TAKE CHARGE PLUS APPENDIX A: DIAGNOSIS CODES PAGE(S) 9

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

I have no financial interests to disclose.

PAP SMEAR by Dr.Shantha Krishnamurthy MD Senior Consultant Pathology Fortis Hospitals

Promoting Cervical Screening Information for Health Professionals. Cervical Cancer

National Cervical Screening Program MBS Item Descriptors

Cervical Cancer Screening. David Quinlan December 2013

Female Reproduc.ve System. Kris.ne Kra7s, M.D.

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

!"#$%&'(#)*$+&,$-&.#,$/#0()1-$ ),1')$2(%&,2#,%$%(0'#$34567$

Alabama Department of Public Health County Health Department Protocol

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

LABORATORY - PELVIC EXAM STUDIES COLPOSCOPY RESULTS FORM L14

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Study Number: Title: Rationale: Phase: Study Period Study Design: Centres: Indication Treatment: Objectives: Primary Outcome/Efficacy Variable:

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

Cervical Cancer Prevention Month. January 2011 Morehouse College

International Journal of Biological & Medical Research

Lessons From Cases of Screened Women Who Developed Cervical Carcinoma

What is HPV and why is it so important?

Prepared By Jocelyn Palao and Layla Faqih

Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.

Estimated New Cancers Cases 2003

Cervical Dysplasia and HPV

Case. Questions Diseases of the Genital System and the Breast

CERVIX. MLS Basic histological diagnosis MLS HIST 422 Semester 8- batch 7 L12 : Dr. Ali Eltayb.

Colposcopy. Attila L Major, MD, PhD

Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.

CONFRONTING CERVICAL CANCER

CLINICAL MEDICAL POLICY

Cervical Testing and Results Management. An Evidenced-Based Approach April 22nd, Debora Bear, MSN, MPH

Reproductive System Disorders

FY16 BCCS Reimbursement Rates and Billing Guidelines Appendix B 2

Should Anal Pap Smears Be a Standard of Care in HIV Management?

Study population The study population comprised women residing in Keelung, northern Taiwan.

EU guidelines for reporting gynaecological cytology

MEDICAL POLICY SUBJECT: MAMMOGRAPHY: COMPUTER- AIDED DETECTION (CAD) POLICY NUMBER: CATEGORY: Technology Assessment

Alabama Breast and Cervical Cancer Early Detection Program (ABCCEDP) County Health Department Protocol

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX


We re on the Web! Visit us at VOLUME 19 ISSUE 1. January 2015

ANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION

Transcription:

ICD-9-CM to ICD-10-CM DIAGNOSIS CODE MAPPING Central Valley Public Health: Women's Way ICD-9-CM (Top 35) ICD-10-CM ICD-10-CM Description COMMENTS V10.3: Personal history of malignant neoplasm of Z85.3 Personal history of malignant neoplasm of V10.41: Personal history of malignant Z85.41 Personal history of malignant neoplasm of cervix uteri V13.22: Personal history of cervical Z87.410 Personal history of cervical dysplasia dysplasia V16.3: Family history of malignant Z83.0 Family history of malignant neoplasm of neoplasm of V67.01: Follow-up vaginal pap smear Z01.42 Encounter for cervical smear to confirm findings of recent normal smear following initial abnormal smear Z08 Z09 Encounter for follow-up examination after completed treatment for malignant neoplasm Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm Z12.4 Encounter for screening for malignant neoplasm of cervix Please see all available options. Concept has been altered. V70.0: Routine general medical examination at a health care facility V72.31: Routine gynecological examination V72.32: Encounter for Papanicolaou cervical smear to confirm findings of recent normal smear following initial abnormal smear Z01.411 Encounter for gynecological examination (general) (routine) with abnormal findings Z01.419 Encounter for gynecological examination (general) (routine) without abnormal findings Z00.00 Encounter for general adult medical examination without abnormal findings Z00.01 Encounter for general adult medical examination with abnormal findings Z01.411 Encounter for gynecological examination (general) (routine) with abnormal findings Z01.419 Encounter for gynecological examination (general) (routine) without abnormal findings Z01.42 Encounter for cervical smear to confirm findings of recent normal smear following initial abnormal smear Use this code if pap smear is a part of a routine gynecological examination. Use this code if pap smear is a part of a routine gynecological examination. Added concept of whether abnormal findings are present. Use additional code(s) to identify abnormal findings when present. Added concept of whether abnormal findings are present. Use additional code(s) to identify abnormal findings when present.

V73.81: Screening for Human papillomavirus [HPV] Z11.51 Encounter for screening for human papillomavirus (HPV) V76.10: Screening for malignant neoplasm of V76.11: Screening mammogram for highrisk patient Z12.39 Encounter for other screening for malignant neoplasm of Z12.31 Encounter for screening mammogram for malignant neoplasm of Z12.31 Encounter for screening mammogram for malignant neoplasm of V76.12: Other screening mammogram Z12.31 Encounter for screening mammogram for malignant neoplasm of V76.19: Other screening examination Z12.39 Encounter for other screening for malignant neoplasm of V76.2: Screening for malignant neoplasm of the cervix V76.47: Screening for malignant neoplasm of the vagina V88.01: Acquired absence of both cervix and uterus V88.02: Acquired absence of uterus with remaining cervical stump V88.03:Acquired absence of cervix with remaining uterus 793.80: Abnormal mammogram, unspecified If type of screening is mammogram, Z12.31 should be used. Screening code no longer specifies whether the patient is high risk in ICD-10. If a personal or family history of neoplasm exists, it should be coded additionally with the appropriate history code. This code should only be used if the condition being screened for is malignancy. Z12.4 Encounter for screening for malignant neoplasm of cervix When pap smear is a part of a routine gynecological examination, use codes Z01.411 or Z01.419. Z12.72 Encounter for screening for malignant neoplasm of vagina Z90.710 Acquired absence of both cervix and uterus Z90.711 Acquired absence of uterus with remaining cervical stump Z90.712 Acquired absence of cervix with remaining uterus R92.8 Other abnormal and inconclusive findings on diagnostic imaging of R92.2 Inconclusive mammogram 793.81: Mammographic microcalcification 610.0: Solitary cyst of R92.0 Mammographic microcalcification found on diagnostic imaging of R92.1 Mammographic calcification found on diagnostic imaging of N60.01 Solitary cyst of right Laterality has been added. Calcifications on mammogram should be specified as microcalcifications to report code R92.0. A unique code now exists for 'calcifications' found on mammogram. N60.02 Solitary cyst of left

611.0: Inflammatory disease of N61 Inflammatory disorders of Includes: abscess of areola, abscess of, mastitis, infective mastitis, carbuncle of. 611.72: Lump or mass in N63 Unspecified lump in Includes: nodule(s) in NOS 622.10: Dysplasia of cervix, unspecified N87.9 Dysplasia of cervix uteri, unspecified For most appropriate code selection, the severity of cervical dysplasia should be specified. 622.11: Mild dysplasia of cervix N87.0 Mild cervical dysplasia Cervical intraepithelial neoplasia I 622.12: Moderate dysplasia of cervix N87.1 Moderate cervical dysplasia Cervical intraepithelial neoplasia II 622.2: Leukoplakia of cervix (uteri) N88.0 Leukoplakia of cervix uteri 623.0: Dysplasia of vagina N89.0 Mild vaginal dysplasia Levels of severity may be captured in code selection in ICD- 10. N89.1 Moderate vaginal dysplasia N89.3 Dysplasia of vagina, unspecified 626.6: Metrorrhagia N92.1 Excessive and frequent menstruation with irregular cycle 627.1: Postmenopausal bleeding N95.0 Postmenopausal bleeding 795.08: Unsatisfactory cervical cytology smear 785.6: Enlargement of lymph nodes R87.615 Unsatisfactory cytologic smear of cervix R59.0 Localized enlarged lymph nodes 795.00: Abnormal glandular Papanicolaou smear of cervix R59.1 Generalized enlarged lymph nodes R59.9 Enlarged lymph nodes, unspecified R87.619 Unspecified abnormal cytological findings in specimens from cervix uteri R87.610 Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US) R87.611 Atypical squamous cells cannot exclude high grade squamous intraepithelial lesion on cytologic smear of cervix (ASC-H) R87.612 Low grade squamous intraepithelial lesion on cytologic smear of cervix (LGSIL) R87.613 High grade squamous intraepithelial lesion on cytologic smear of cervix (HGSIL) R87.614 Cytologic evidence of malignancy on smear of cervix If abnormal findings may be specified as one of the below listed codes, a higher level specificity code should be selected. R87.618 Other abnormal cytological findings on specimens from cervix uteri

174.9: Malignant neoplasm of (female), unspecified C50.011 Malignant neoplasm of nipple and areola, right female Concept of laterality has been added. Unspecified laterality option excluded. 174.9 by definition reflects an unspecified site: question appropriateness of this code reported at such high rates. C50.012 Malignant neoplasm of nipple and areola, left female C50.111 Malignant neoplasm of central portion of right female C50.112 Malignant neoplasm of central portion of left female C50.211 Malignant neoplasm of upper-inner quadrant of right female C50.212 Malignant neoplasm of upper-inner quadrant of left female C50.311 Malignant neoplasm of lower-inner quadrant of right female C50.312 Malignant neoplasm of lower-inner quadrant of left female C50.411 Malignant neoplasm of upper-outer quadrant of right female C50.412 Malignant neoplasm of upper-outer quadrant of left female C50.511 Malignant neoplasm of lower-outer quadrant of right female C50.512 Malignant neoplasm of lower-outer quadrant of left female C50.611 Malignant neoplasm of axillary tail of right female C50.612 Malignant neoplasm of axillary tail of left female C50.811 Malignant neoplasm of overlapping sites of right female C50.812 Malignant neoplasm of overlapping sites of left female C50.911 Malignant neoplasm of unspecified site of right female C50.912 Malignant neoplasm of unspecified site of left female 180.9: Malignant neoplasm of Cervix uteri, unspecified C53.9 Malignant neoplasm of cervix uteri, unspecified Site should be specified to highest extent possible. C53.0 Malignant neoplasm of endocervix C53.1 Malignant neoplasm of exocervix

C53.8 Malignant neoplasm of overlapping sites of cervix uteri